Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Annovis Bio, Inc. (ANVS)
|
Add to portfolio |
|
|
|
| Price: |
$18.86
| | Metrics |
| OS: |
9.01
|
M
| |
-145
|
% ROE
|
| Market cap: |
$170
|
M
| |
-527
|
% ROIC
|
|
Net cash:
|
$15.7
|
M
| |
$1.74
|
per share
|
|
EV:
|
$154
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($30.6)
|
M
| |
|
|
|
EBIT
|
($30.6)
|
M
| |
|
|
| EPS |
($3.57)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 |
| Revenue growth | | | | -100.0% | -59.2% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.5 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | -0.6 | -0.3 |
| Gross margin | | | | | -539.7% | -100.0% |
| Research and development | 16.5 | 8.5 | 3.1 | 0.8 | | |
| General and administrative | 9.0 | 6.1 | 3.6 | 0.8 | 0.6 | 0.4 |
| EBIT | -25.5 | -14.5 | -6.6 | -1.6 | -0.7 | -0.7 |
| EBIT margin | | | | | -639.7% | -249.6% |
| Pre-tax income | -25.3 | -14.5 | -5.5 | -1.0 | -0.7 | -0.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -25.3 | -14.5 | -5.5 | -1.0 | -0.7 | -0.7 |
| Net margin | | | | | -639.6% | -249.6% |
| |
| Diluted EPS | ($3.10) | ($1.90) | ($0.87) | ($3.51) | ($2.57) | ($2.66) |
| Shares outstanding (diluted) | 8.2 | 7.6 | 6.3 | 0.3 | 0.3 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|